ArticleInternal medicine (Tokyo, Japan)2023
Risk Factors Related to Severity in COVID-19 Patients: A Real-world Retrospective Cohort Study.
Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Machine learning models for the prediction of COVID-19 prognosis in the primary health care setting.BMC primary care · 2025Article
- The Relationship Between Kidney Biomarkers, Inflammation, Severity, and Mortality Due to COVID-19-A Two-Timepoint Study.International journal of molecular sciences · 2025Article
- Clinical characteristics of coronavirus disease 2019 in patients undergoing laparoscopic bariatric/metabolic surgery: a nationwide survey in Japan.Surgery today · 2025Article
- Repeated Syncope Following COVID-19 Infection.Internal medicine (Tokyo, Japan) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Understanding the clinical factors associated with the severity of coronavirus disease 2019 (COVID-19) is very important for the effective use of limited medical resources, including the appropriate evaluation of the need for hospitalization and discharge. Methods Patients hospitalized with a diagnosis of COVID-19 from March 2021 to October 2022 were included in the study. Patients admitted to our facility were classified into four waves: 4th (April to June 2021), 5th (July to October 2021), 6th (January to June 2022), and 7th waves (July to October 2022). We analyzed the severity, patients' background characteristics, presence of pneumonia on chest computed tomography (CT), and blood test results in each wave. Patients were further classified into respiratory failure and nonrespiratory failure groups and statistically compared. Results Of the 565 patients diagnosed with COVID-19, 546 were included in this study. The percentage of patients classified as mild was approximately 10% in the 4th and 5th waves, but the rate increased after the 6th wave, with rates of 55.7% and 54.8% in each wave. Although more than 80% of patients in the 4th and 5th waves showed pneumonia on chest CT, the percentage decreased to approximately 40% after the 6th wave. Further comparisons between the respiratory failure group (n=75) and the nonrespiratory failure group (n=471) revealed significant differences in the age, sex, vaccination history, and biomarker values between the two groups. Conclusion In this study, elderly men were found to be more likely to develop severe disease than others, and biomarkers of COVID-19, such as C-reactive protein and lactate dehydrogenase, were useful for predicting severity. This study also suggested that vaccination may have contributed to a reduced disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.